Hypoxic hypoxia, including abnormally low partial pressure of inhaled oxygen, external respiratory dysfunction-induced respiratory hypoxia and venous blood flow into the arterial blood, is characterized by decreased arterial oxygen partial pressure, resulting in tissue oxygen deficiency. The specific characteristics include reduced arterial oxygen partial pressure and oxygen content. Hypoxic hypoxia diseases 
to left shunt congenital heart disease and pulmonary hypertension).
Endothelial microvesicles are 100-1000 nm anucleated vesicles formed following cytoskeletal and membrane reorganization and are released during apoptosis or activation of ECs into the extracellular milieu. 5, 6 EMVs that are released from apoptotic or activated ECs that have been stimulated by hypoxia, oxidative stress, coagulation and inflammation can be used as a marker of EC injury. Coincidentally, elevated EMV levels have been identified in several HHDs, 7 including OSA 8 and pulmonary hypertension (PH). 9 Furthermore, EMVs play a critical role in cell information transmission and exchange, and the procoagulant, proinflammatory and angiogenic properties of EMVs have been confirmed to increase in the occurrence and development of HHDs. All these findings indicate that
EMVs have the potential to identify HHD phenotypes, to stratify disease severity, to improve risk stratification for patients who develop HHDs, to better define prophylactic strategies and to ameliorate the prognostic characterization of patients with HHDs. Furthermore, because a pathogenic role for EMVs is clearly emerging in HHDs, EMVs are becoming a novel target for HHD treatment.
| END OTHELIAL MICROVESICLES
Endothelial microvesicles are 100-1000 nm anucleated vesicles that are formed following cytoskeletal and membrane reorganization and can be released into the extracellular milieu following apoptosis or activation of ECs. 5, 10 Hypoxia, ischaemia, oxidative stress, inflammation, coagulation and other factors can damage ECs or cause EC activation. 11 Previous studies also found elevated EMV levels in several disease conditions associated with hypoxic hypoxia, 7 such as OSA, 8 chronic obstructive pulmonary disease (COPD) 12 and PH. 9 In addition, EMVs may play important roles in the pathological processes 13 and tissue repair mechanisms 14 of HHDs.
| EMV phenotypes
As the surface of EMVs contains a variety of membrane glycoprotein antigens (such as CD31, CD144 and others), EMVs can be defined and detected using membrane glycoprotein antigens. These membrane glycoprotein antigens also make it easier to identify, distinguish and study EMVs.
First, membrane glycoprotein antigens help us to identify EMVs.
We can use membrane glycoprotein antigens to detect and identify
EMVs. However, a major issue is that most surface markers are not unique to EMVs. In the blood, platelets, red blood cells and other cells can release microvesicles, and many different cell-derived microvesicles have common surface markers. To identify EMVs and distinguish EMVs from other vesicles, researchers have proposed a combination of marker proteins derived from different vesicles to resolve these difficulties. For example, we can use positive EC markers (eg CD31 and CD144) in combination with the absence of platelet markers (CD41 or CD42b) to distinguish between EMV and platelet microvesicles. 15 As shown in our previous report 16 and in Figure 1 , the existing CD markers on the surface of Third, different surface markers likely play different roles in the pathogenesis of diseases. 22 As shown in Table 1 , different EMV subtypes may play a role in different HHDs. The level of CD31 + EMVs is related to the apnoea-hypopnea index (AHI) in OSA patients [23] [24] [25] ; mild COPD and emphysema in COPD patients 26, 27 ; and hemodynamic severity, risk stratification and treatment effects in PH patients. 9, 28, 29 
| EMVs as messengers
As shown in Figure 1 , 10, 11, [17] [18] [19] [20] [21] EMVs can be used as an indicator to reflect stimulatory factors, the disease state and prognosis. In contrast, EMVs also play a role in pathological processes and disease development. EMVs have important functions in the inflammatory response, coagulation and angiogenesis. As shown in Figure 2 , 17, 49 we identified the signal pathways involved in thrombin-induced EMV formation and potential mechanisms involving in circulating EMVs in the interrelationship among inflammation, angiogenesis, and coagulation. We previously published an article detailing these features of EMVs; thus, for more detailed information, please refer to our previously published paper. 16 
| EMVS IN HHDS
Endothelial microvesicles have been investigated in several human
HHDs, which include very low partial pressure of inhaled oxygen, external respiratory dysfunction-induced respiratory hypoxia and venous blood flow into the arterial blood, as possible pathogenic elements, prognostic markers, and therapeutic targets. The data reported in the following sections are summarized in Table 2 .
| EMVs and atmospheric hypoxia
When people are at an altitude of 3000 metres above sea level or at a high altitude, are in poor ventilation tunnels or inhale a hypoxic mixture, the amount of oxygen in the body first depends on the oxygen partial pressure of the inhaled gas. In a plateau, as the altitude increases, the atmospheric pressure decreases, and the partial pres- declined with increasing sea level. 50 We believe that this difference is attributable to CD31 + EMVs (primarily released from apoptotic ECs and reflecting hypoxia-induced acute injury, while CD62E + EMVs are primarily released from activated ECs). As Table 2 shows, however, the results of different groups are not consistent or even 
| EMVs and Asthma
Asthma is usually characterized by different patterns of airway inflammation with a complex network of cellular and molecular mediators. 61 In contrast to OSA, very little is known about the possible role of EMVs in asthma. The scarce available data are preliminary, and further research in the field with properly designed studies is needed. 
| EMVs and COPD

| EMVs and PH
Vascular remodelling and endothelial dysfunction-related EMVs are involved in PH. 64 Three research groups have demonstrated that EMV levels were significantly higher in PH patients than controls.
The levels of CD31 + EMVs and CD144 + EMVs, but not those of CD62E + EMVs, predict hemodynamic severity in PH patients. 9 Elevated levels of circulating CD62E + EMVs in PH patients prior to treatment were associated with adverse clinical events. 41 The levels of CD144 + EMVs were positively associated with pulmonary artery intima media thickness but not CD146 + EMVs. 46 69 The role of EMVs in inducing ALI/ARDS and endothelial dysfunction may present new therapeutic targets. 70 Finally, in a murine model, the injection of EMVs into mice induced a significant release of the proinflammatory cytokines TNFa and IL-1b and a subsequent recruitment of neutrophils. 70 These effects were further increased by the concomitant or sequential administration of bacterial LPS, indicating that EMVs might represent a signal that primes the lung for the following inflammatory response to an external injury. 71 Again, from this point of view, EMVs could represent a potential therapeutic target for ALI/ARDS. EMVs could be a link between alveolar inflammation and coagulation (2 key steps in the pathobiology of ALI/ARDS) and may be a target for future treatment.
| EMVs and venous thromboembolism/ pulmonary embolism
The pathophysiology of VTE involves endothelial damage, blood stasis and hypercoagulability. 72 EMVs may be used as diagnostic and differential diagnostic criteria in VTE and PE. EMV levels were significantly higher in patients with VTE, 43, 73 a previous VTE history, 74, 75 and the prothrombin gene mutation G20210A (PTM) compared with controls. 74 This finding implies that elevated levels of circulating CD62E + EMVs act as carriers of mild and severe inherited thrombophilia and may contribute to the development of VTE in factor V Leiden (FVL) mutation carriers. In addition, EMVs are also involved in disease pathophysiology. Chirinos et al. found that patients with VTE showed marked elevation of EMV generation and EMV-monocyte conjugates. 73 These findings indicate that EMV release and binding to monocytes are key events in thrombogenesis.
However, Bal et al. found that circulating procoagulant MV levels were significantly higher in acute PE patients than in healthy control subjects with no history of VTE or vascular risk factors. 76 Meanwhile, CD31 + EMV levels were not significantly changed. 76 This discrepancy may be due to population and EMV subpopulation differences. 
| CIRCULATIN G EMVs WITH DISTINCT MICRORNAS CARGO IN H HDS
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